文献速递细菌感染、耐药与抗菌药物

2007至2016年中国临床分离大肠埃希菌和肺炎克雷伯菌中mcr-1的回顾性研究

A retrospective study on mcr-1 in clinical Escherichia coli and Klebsiella pneumoniae isolates in China from 2007 to 2016.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

该研究收集2007年1月至2016年6月中国18至20家医院住院患者的6264株临床大肠埃希菌和肺炎克雷伯菌,用PCR筛查mcr-1基因,发现39株(0.62%)阳性,阳性株对哌拉西林、阿米卡星、呋喃妥因和磷霉素的耐药性显著高于阴性株,ESBL产生率84.6%,92.3%为MDR表型。

要点

  • mcr-1阳性大肠埃希菌和肺炎克雷伯菌总检出率为0.62%(39/6264)。
  • mcr-1阳性株耐药性显著高于阴性株,涉及哌拉西林、阿米卡星、呋喃妥因和磷霉素。
  • mcr-1阳性株中ESBL产生率84.6%,92.3%显示MDR表型。

核心结论

  • mcr-1阳性大肠埃希菌和肺炎克雷伯菌在中国大陆 prevalence 较低且系统发育多样性丰富。
  • mcr-1阳性大肠埃希菌与阴性株的耐药谱存在显著差异,提示医生面对mcr-1阳性病原体感染时可考虑处方不同抗生素。

研究设计与样本

  • 回顾性研究,收集2007年1月至2016年6月中国18至20家医院住院患者的临床大肠埃希菌(n=3854)和肺炎克雷伯菌(n=2410),共6264株。
  • 采用PCR筛查所有分离株的mcr-1基因,肉汤微量稀释法进行药敏试验,阳性株用MLST和基于BURST算法的最小生成树分析。

主要发现

  • 10年间共检出39株(0.62%)mcr-1阳性临床大肠埃希菌和肺炎克雷伯菌。
  • mcr-1阳性株对哌拉西林(P=0.008)、阿米卡星(P<0.0001)、呋喃妥因(P<0.004)和磷霉素(P<0.0001)的耐药性显著高于mcr-1阴性株。
  • mcr-1阳性株中ESBL产生率为84.6%(33/39),92.3%(36/39)显示MDR表型。
  • ST型提示mcr-1携带病原体广泛传播。

临床怎么用

  • 作者认为,面对mcr-1阳性病原体引起的感染,医生可考虑处方不同抗生素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the prevalence of clinical mcr-1-positive Escherichia coli and Klebsiella pneumoniae and characterize the antimicrobial resistance profiles of mcr-1-positive E. coli and mcr-1-negative E. coli in China. METHODS: A total of 6264 clinical E. coli (n = 3854) and K. pneumoniae (n = 2410) were collected from hospitalized patients from 18 to 20 hospitals as part of the China Antimicrobial Resistance Surveillance Trial (CARST) between January 2007 and June 2016. PCR was used to screen for the mcr-1 gene among all isolates. Antibiotic susceptibility testing was performed using the broth microdilution method. mcr-1-positive pathogens were then characterized by MLST and minimum spanning tree analysis using the BURST algorithm for related STs. RESULTS: We examined 39 (0.62%) clinical isolates of mcr-1-positive E. coli and K. pneumoniae over a 10 year period. Resistance to antimicrobial agents was significantly more severe in mcr-1-positive isolates than mcr-1-negative isolates, particularly piperacillin (P = 0.008), amikacin (P < 0.0001), nitrofurantoin (P < 0.004) and fosfomycin (P < 0.0001). Among mcr-1-carrying isolates, ESBL production was as high as 84.6% (33 of 39) and 92.3% (36 of 39) of them displayed an MDR phenotype. STs suggested ubiquitous dissemination of mcr-1-carrying pathogens. CONCLUSIONS: mcr-1-carrying E. coli and K. pneumoniae displayed a lower prevalence and abundant phylogenetic diversity in mainland China. mcr-1-positive E. coli showed significant differences in antimicrobial resistance profiles compared with mcr-1-negative E. coli strains, suggesting physicians may consider prescribing different antibiotics when faced with infections caused by mcr-1-positive pathogens.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Liu X, Wang Y, Cui L, et al. A retrospective study on mcr-1 in clinical Escherichia coli and Klebsiella pneumoniae isolates in China from 2007 to 2016. J Antimicrob Chemother. 2018. PMID: 29912359. doi:10.1093/jac/dky092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。